calmodulin

Calmidazolium chloride (R 24571) is a calmodulin (CaMK) antagonist with a Kd of 3 nM, which inhibits CaM-dependent phosphodiesterase (IC50 = 0.15 μM) and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase (IC50 = 0.35 μM). It also induces apoptosis in certain cancer cell lines.

Zaldaride maleate inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity (IC50: 3.3 nM). Zaldaride maleate is an effective and selective inhibitor of calmodulin. Zaldaride maleate prevents estrogen-induced transcription activation by ER, re

W-7 hydrochloride (W-7 HCl), a calmodulin antagonist, inhibits Ca2+-calmodulin-dependent myosin light chain kinase and phosphodiesterase, W-7 hydrochloride induces apoptosis and has antitumor activity.

A-7 hydrochloride is a calmodulin antagonist and causes alterations in the subpopulation of CD44+CD24- in MDA-MB-231 cells.

W-13 hydrochloride (W-13 HCl) is a calmodulin antagonist.

W-9 hydrochloride is a calmodulin antagonist.

Psoralenoside is a natural product isolated from the fruits of Psoralea corylifolia, shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity.

CALP2 acetate is an antagonist of calmodulin showing high affinity for binding to the CaM EF-hand/Ca2+-binding site with a Kd of 7.9 µM. CALP2 acetate potently inhibits of adhesion and degranulation. CALP2 acetate is also a strong activator of alveolar macrophages. CALP2 acetate inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca2+ concentrations.

CALP1 acetate is a calmodulin (CaM) agonist (Kd of 88 µM) that binds to the CaM EF-hand/Ca2+-binding site. CALP1 blocks calcium influx and apoptosis (IC50 of 44.78 µM) by inhibiting the open of calcium channel. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity.

Elziverine is an orally available small molecule calmodulin antagonist.Elziverine in vitro treatment inhibited Ca-loading-induced acanthocyte formation in SHRSP, WKY, and Wistar rats in a concentration-dependent manner.Elziverine can be used for the treatment of neurological disorders, and may be used for the study of cognitive disorders.

Calmodulin antagonist-1 (W-7) is a calmodulin (CaM) antagonist that effectively inhibits calmodulin-activated Ca 2+ -phosphodiesterase (PDE) with an IC 50 of 28 μM. This compound also competitively inhibits trypsin-treated Ca 2+ -PDE with respect to cyclic GMP, exhibiting an IC 50 of 375 μM and a K i value of 300 μM.

Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for the inhibition of Ca2+/calmodulin-dependent protein kinase II [1].

Calmodulin-Dependent Protein Kinase Substrate Analog, a synthetic peptide substrate, is activated by Ca2+ and calmodulin (CaM). It serves as a substrate for protein kinases, leveraging a dependency on Ca2+ and CaM for its function [1].

Calmodulin Dependent Protein Kinase Substrate is a synthetic peptide that interacts specifically with calmodulin-dependent protein kinases (CaMK) and requires calcium ions (Ca 2+) and calmodulin (CaM) for activation. It is utilized in studies involving protein kinase activity [1].

Myristoylated Calmodulin Kinase IINtide (Myr-CaMKIINtide) serves as a selective and noncompetitive inhibitor of CaMKII [1].

Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibiting Ca2+/calmodulin-dependent protein kinase II.

Calmodulin-Dependent Protein Kinase II 290-309 acetate is an effective antagonist of Ca2+/calmodulin-dependent protein kinase II (IC50 = 52 nM).

Calmodulin Binding Peptide 1, a potent CaM-binding peptide with picomolar (pM) affinity, originates from smooth muscle myosin light-chain kinase (MLCK peptide). It effectively blocks inositol trisphosphate (IP3)-induced calcium (Ca2+) release [1].

Calmodulin-Dependent Protein Kinase II (281-309) is a synthetic peptide phosphorylatable at Thr286 by PKC, inhibiting CaM kinase II with an IC50 of 80 nM.

[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of the calcium ion/calcium-binding protein-dependent kinase II (CaMKII), featuring the active region of CaMKII with an alanine substitution at position 286. This particular modification allows for the potential development of more effective CaMKII inhibitors.

SGC-CAMKK2-1 is a selective inhibitor of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC50 of 30 nM. It effectively inhibits AMPK phosphorylation in C4-2 cells, exhibiting an IC50 value of 1.6 µM.

CBP-501 acetate is a cell-permeable calmodulin-binding peptide and a candidate G2 phase checkpoint abrogator. It inhibits several Ser216-specific kinases, including MAPKAP-K2, C-Tak1, CHK1, and CHK2, with IC50 values of 0.9 μM, 1.4 μM, 3.4 μM, and 6.5 μM, respectively. CBP-501 acetate is applicable to various cancer research studies.

Tiflucarbine is a potential non-selective 5-HT agonist with antidepressant activity.Tiflucarbine dose-dependently increased the specific activity of soluble calmodulin (CaM)-dependent phosphodiesterase in rat brain.

Flunarizine dihydrochloride (R14950) is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. Flunarizine dihydrochloride (R14950) is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.